Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England.
about
Cost-effectiveness of pneumococcal vaccination strategies for the elderly in KoreaPneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian Regional Experience.Effectiveness of 23-valent pneumococcal polysaccharide vaccination in preventing community-acquired pneumonia hospitalization and severe outcomes in the elderly in SpainThe impact of community-acquired pneumonia on the health-related quality-of-life in elderlyForecasting Trends in Invasive Pneumococcal Disease among Elderly Adults in Quebec.Community-acquired pneumonia in the United Kingdom: a call to action.The full benefits of adult pneumococcal vaccination: A systematic review.Pneumococcal vaccination in older persons: where are we today?Cost-effectiveness of the Haemophilus influenzae type b vaccine for infants in mainland China.Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands.Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations.Elucidating the impact of the pneumococcal conjugate vaccine programme on pneumonia, sepsis and otitis media hospital admissions in England using a composite control.Economic Evaluation of Pneumococcal Vaccines for Adults Aged Over 50 Years in Belgium.Incidence and case fatality rates of community-acquired pneumonia and pneumococcal diseases among Korean adults: Catchment population-based analysis.Vaccination programs for older adults in an era of demographic change.Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South KoreaA recombinant conjugated pneumococcal vaccine that protects against murine infections with a similar efficacy to Prevnar-13
P2860
Q33675229-B99E74E6-CC3E-4E94-B331-DA85B4A07019Q36192851-7F881B13-45EA-43DA-96C6-F19A2C760B66Q36277159-6C845191-E817-4B87-B70B-0BD00139E2AFQ36307771-AB6B48A5-1C57-45D5-9E12-EC7CCCD05946Q37633201-C91ABF9E-2AB8-4893-8667-7748E095F075Q42370480-5149A702-CA73-4D19-8852-5482EB2D7B30Q47098784-578B462B-702C-413B-9FE9-C5539E409398Q47221369-A5FA21D5-DA6D-49D8-8D13-93B680A5C924Q48161377-7A7E8250-2A06-443D-87BB-5FFC3F76CCF5Q48504188-D88A015A-AB84-41D5-82F9-A3C921627693Q48563045-4913A033-DE50-4CDD-B6AD-17C33D5BEAF6Q49459405-302ED6D6-C4BF-445D-90F8-FAFE43B55104Q50116116-C136240D-39CA-4E2B-9EFA-D017C06CA891Q54245877-6CDFBC0B-E949-4A15-92DB-6AB86C795D8DQ54963907-A3EE2194-263F-4A54-8095-9273D9D9C3F6Q57211903-8891F82F-75EB-4083-846E-769FB6F52B8EQ58587115-0FBCD3A4-7625-468C-B40E-449D64F0CFDA
P2860
Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Cost-Effectiveness of Vaccinat ...... Conjugate Vaccine in England.
@ast
Cost-Effectiveness of Vaccinat ...... Conjugate Vaccine in England.
@en
type
label
Cost-Effectiveness of Vaccinat ...... Conjugate Vaccine in England.
@ast
Cost-Effectiveness of Vaccinat ...... Conjugate Vaccine in England.
@en
prefLabel
Cost-Effectiveness of Vaccinat ...... Conjugate Vaccine in England.
@ast
Cost-Effectiveness of Vaccinat ...... Conjugate Vaccine in England.
@en
P2860
P1433
P1476
Cost-Effectiveness of Vaccinat ...... Conjugate Vaccine in England.
@en
P2093
Albert Jan van Hoek
Elizabeth Miller
P2860
P304
P356
10.1371/JOURNAL.PONE.0149540
P407
P577
2016-02-25T00:00:00Z